Skip to content

Patient acceptability of FIT stool test and analysing a colorectal cancer risk tool

Understanding reasons why patients with colorectal symptoms do not use the faecal immunochemical test when offered and analysing a risk tool for colorectal cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ISRCTN
Registry ID
ISRCTN87120188
Enrollment
15
Registered
2023-01-16
Start date
2022-11-19
Completion date
Unknown
Last updated
2024-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal cancer Cancer

Interventions

An observational study in two parts: Part 1: Patients who have been referred to Croydon University Hospital from primary care within Croydon CCG under the colorectal 2-week wait pathway which uses th

Sponsors

Croydon University Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Study 1: 1. Patients who have been offered but have not used FIT as part of their referral from primary to secondary care colorectal department within Croydon CCG but who have not completed a FIT (Referral via FIT Implementation pathway). 2. Adults (aged 18 to 110 years) 3. Patients will be able to read, understand and communicate their understanding of the patient information form and complete the consent form 4. Patients will be able to conduct telephone interviews in English Study 2: 1. Patients who have been referred to Croydon University Hospital under the FIT Implementation pathway 2.1. Patients who have recorded: FHb, serum Hb, ferritin, age, gender and CRP as well as 2-week wait pathway diagnosis in electronic medical notes or: 2.2. Patients who have recorded: FHb, serum Hb, ferritin, age and gender as well as 2-week wait pathway diagnosis in electronic medical notes

Exclusion criteria

Exclusion criteria: Study 1: 1. Patients not offered FIT as part of 2-week wait referral 2. Patients not able to read, understand and communicate their understanding of the patient information form and consent form 3. Patients not able to conduct telephone interviews in English Study 2: 1. Patients not referred under 2-week wait pathway to hospital 2. Patients without recorded faecal haemoglobin recorded 3. Patients with inadequate biochemical parameters recorded

Design outcomes

Primary

MeasureTime frame
Study 1: Perceived barriers to using the faecal immunochemical test (FIT) for patients who have declined to use the test when offered it as part of their investigations for potential colorectal cancer symptoms, measured using qualitative interviews, completed after patient investigations and diagnosis completed. Analysis through grounded theory analysis. Study 2: Factors that would increase the likelihood of patients using FIT when offered as an initial investigation for suspected colorectal cancer symptoms, measured using qualitative interviews, completed after patient investigations and diagnosis completed. Analysis through grounded theory analysis.

Secondary

MeasureTime frame
Study 1: Diagnostic accuracy of colorectal cancer risk tool compared to faecal haemoglobin alone, measured through predicted % risk of colorectal cancer using risk tool and % risk of colorectal cancer using faecal haemoglobin alone, compared to diagnostic cancer outcomes of patients following completion of two weeks wait investigations. Study 2: Sensitivity and specificity of risk tool for colorectal cancer measured by selecting % of patients predicted to have colorectal cancer at set risk thresholds compared to diagnostic cancer outcomes of patients following completion of two-week wait investigations.

Countries

England, United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026